Engineered immune cells offer new hope for kids with Tough-to-Treat leukemia
NCT ID NCT04787263
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 16 times
Summary
This study tests a personalized treatment where a child's own immune cells are modified in a lab to recognize and attack cancer cells that have a protein called CD19. It is for children and young adults with certain types of leukemia or lymphoma that have come back or not responded to standard treatments. The goal is to find the safest and most effective dose and see how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IRCCS Ospedale Pediatrico Bambino Gesù
Roma, 00165, Italy
Conditions
Explore the condition pages connected to this study.